Mylan has launched Lithium Carbonate Extended-release Tablets USP, 450 mg following the final approval from the US Food and Drug Administration (FDA).
The drug is used to treat manic episodes of manic depressive illness.
According to IMS Health, Lithium Carbonate Extended-release Tablets USP, 450 mg, had US sales of around $15.2m for the 12 months ending 30 June 2012.
Mylan currently, has 166 Abbreviated New Drug Applications (ANDAs) pending FDA approval.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/mylan-introduces-lithium-carbonate-extended-release-tablets-usp-130812
